Avicanna Reports Positive Adjusted EBITDA for Q3 2026 and Provides Corporate Update

Adjusted EBITDA of $0.22 million, improves $1.01 million year-over-year, operating loss narrows by 80%Proprietary products reach 31% of MyMedi.ca sales, up from 19%; QUIX™ launches with 10 SKUsTORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) TSX:AVCN OTCQB:AVCN…